Study details
Enrolling now
Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV
Louisiana State University Health Sciences Center in New Orleans
NCT IDNCT05266898ClinicalTrials.gov data as of Apr 2026
Phase
Phase 4
Target enrollment
250
Study length
about 3.6 years
Ages
18–65
Locations
1 site in LA
What this study is about
This trial is testing how well the Gardasil-9 vaccine works to create antibodies against human papillomavirus (HPV) in adults with HIV. The goal is to see if people living with HIV develop a similar antibody response as those without HIV, and whether the vaccine provides short-term clinical benefit against HPV infections.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Human papillomavirus 9-valent vaccine, recombinant
- 2.Receive human papillomavirus vaccine, recombinant
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Injection / IVInjection / IV
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
vaccine
Drug routes
injection
Body systems
Immune, Infectious